Pharmaceutical company Neuraxpharm Group reported on Wednesday the formation of Neuraxpharm Portugal in Lisbon, expanding its operations in Southern Europe.
Neuraxpharm Portugal will be part of the company's Southern European Region that comprises Italy, Spain and now Portugal.
Through the new subsidiary, Neuraxpharm will leverage its industry networks and central nervous system (CNS) expertise to make its extensive portfolio available to patients. It is planning the first commercial launch in December this year with a probiotic product.
The company aims to build its position as a CNS specialist in Portugal offering its wide portfolio of branded and consumer healthcare products in the Portuguese market.
Javier Mercadé, the general manager of Italy and Spain, was appointed as head of Southern Region earlier this year and Teng Dias has been named as commercial director of the Neuraxpharm Portugal business.
Praxis Precision Medicines raises USD110m in Series C1 financing
Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA
Neuro-Sys introduces in vivo services
FDA Grants Orphan Drug Designation for CNS Pharmaceuticals' Lead Product
FDA announces second approved therapy for neuromyelitis optica spectrum disorder